<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119716</url>
  </required_header>
  <id_info>
    <org_study_id>6621-051</org_study_id>
    <secondary_id>2010_025</secondary_id>
    <nct_id>NCT01119716</nct_id>
  </id_info>
  <brief_title>International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)</brief_title>
  <acronym>RHYTHM-AF</acronym>
  <official_title>International Registry on Cardioversion of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut für Herzinfarktforschung an der Universität Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will create a prospective registry of consecutive patients with Atrial
      Fibrillation (Afib) considered for cardioversion treatment to document up-to-date practice of
      in-hospital treatment, with a focus on the characterization of type of Afib, as well as on
      treatments applied (drugs, devices, interventions and their combinations), and associated
      complications within 60 days after enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission)</measure>
    <time_frame>Baseline (time of admission)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission)</measure>
    <time_frame>Baseline (time of admission)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Type of Atrial Fibrillation at Baseline (Admission)</measure>
    <time_frame>Baseline (time of admission)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatments Utilized for Participants for Atrial Fibrillation</measure>
    <time_frame>At time of Treatment (up to 1 day from admission)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion</measure>
    <time_frame>At time of treatment (up to 1 day from admission)</time_frame>
    <description>Pharmacological cardioversion was considered successful if sinus rhythm or atrial rhythm was obtained within 24 hours after its initiation. Electrical cardioversion was considered successful if sinus rhythm was obtained and maintained for at least 10 minutes after the last shock was administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation</measure>
    <time_frame>up to 60 days from day of treatment (cardioversion)</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4658</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>All Enrolled Participants</arm_group_label>
    <description>Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in a hospital setting in Australia, Brazil, France, Germany, Italy, Netherlands,
        Poland, UK, Spain, and Sweden from a cross section of different centers including
        university and non-university hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant with documented atrial fibrillation (confirmed by electrocardiogram) in
             the hospital setting at the time of enrollment

          -  Planned cardioversion (of atrial fibrillation)

        Exclusion Criteria:

          -  Already enrolled in this or any other clinical trial

          -  Atrial flutter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <results_reference>
    <citation>Crijns HJ, Weijs B, Fairley AM, Lewalter T, Maggioni AP, Martín A, Ponikowski P, Rosenqvist M, Sanders P, Scanavacca M, Bash LD, Chazelle F, Bernhardt A, Gitt AK, Lip GY, Le Heuzey JY. Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. Int J Cardiol. 2014 Apr 1;172(3):588-94. doi: 10.1016/j.ijcard.2014.01.099. Epub 2014 Jan 25.</citation>
    <PMID>24556445</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <results_first_submitted>December 13, 2013</results_first_submitted>
  <results_first_submitted_qc>December 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2014</results_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Afib</keyword>
  <keyword>cardioversion</keyword>
  <keyword>normal sinus rhythm</keyword>
  <keyword>arrhythmia</keyword>
  <keyword>AF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Enrolled Participants</title>
          <description>Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4658"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4658"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Enrolled Participants</title>
          <description>Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4658"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission)</title>
        <time_frame>Baseline (time of admission)</time_frame>
        <population>All enrolled participants with baseline cardiovascular history data.</population>
        <group_list>
          <group group_id="O1">
            <title>Male</title>
            <description>Male participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
          <group group_id="O2">
            <title>Female</title>
            <description>Female participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission)</title>
          <population>All enrolled participants with baseline cardiovascular history data.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2909"/>
                <count group_id="O2" value="1740"/>
                <count group_id="O3" value="4649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Congenital Heart Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sick Sinus Syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="3.5"/>
                    <measurement group_id="O3" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sustained Ventricular Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular Fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission)</title>
        <time_frame>Baseline (time of admission)</time_frame>
        <population>All enrolled participants with co-morbity data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Male</title>
            <description>Male participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
          <group group_id="O2">
            <title>Female</title>
            <description>Female participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
        </group_list>
        <measure>
          <title>Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission)</title>
          <population>All enrolled participants with co-morbity data available.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2851"/>
                <count group_id="O2" value="1711"/>
                <count group_id="O3" value="4562"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chronic Obstructive Pulmonary Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Vascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Renal Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Apnea Syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemorrhagic Complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Type of Atrial Fibrillation at Baseline (Admission)</title>
        <time_frame>Baseline (time of admission)</time_frame>
        <population>All enrolled participants with admission (baseline) atrial fibrillation data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Male</title>
            <description>Male participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
          <group group_id="O2">
            <title>Female</title>
            <description>Female participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Type of Atrial Fibrillation at Baseline (Admission)</title>
          <population>All enrolled participants with admission (baseline) atrial fibrillation data available.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2909"/>
                <count group_id="O2" value="1740"/>
                <count group_id="O3" value="4649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st Detected Episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2"/>
                    <measurement group_id="O2" value="33.6"/>
                    <measurement group_id="O3" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paroxysmal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="31.9"/>
                    <measurement group_id="O3" value="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4"/>
                    <measurement group_id="O2" value="27.6"/>
                    <measurement group_id="O3" value="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Permanent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatments Utilized for Participants for Atrial Fibrillation</title>
        <time_frame>At time of Treatment (up to 1 day from admission)</time_frame>
        <population>All enrolled participants with available data pertaining to type of therapy(s) used to treat the participants atrial fibrillation.</population>
        <group_list>
          <group group_id="O1">
            <title>Male</title>
            <description>Male participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
          <group group_id="O2">
            <title>Female</title>
            <description>Female participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
        </group_list>
        <measure>
          <title>Treatments Utilized for Participants for Atrial Fibrillation</title>
          <population>All enrolled participants with available data pertaining to type of therapy(s) used to treat the participants atrial fibrillation.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2916"/>
                <count group_id="O2" value="1742"/>
                <count group_id="O3" value="4658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Electrical Cardioversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1677"/>
                    <measurement group_id="O2" value="792"/>
                    <measurement group_id="O3" value="2469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pharmacological Cardioversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="705"/>
                    <measurement group_id="O2" value="609"/>
                    <measurement group_id="O3" value="1314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combined Electrical/Pharmacological Cardioversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rate Control Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Catheter Ablation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical Therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Implantable Cardiac Defibrillator</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacemaker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550"/>
                    <measurement group_id="O2" value="342"/>
                    <measurement group_id="O3" value="892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion</title>
        <description>Pharmacological cardioversion was considered successful if sinus rhythm or atrial rhythm was obtained within 24 hours after its initiation. Electrical cardioversion was considered successful if sinus rhythm was obtained and maintained for at least 10 minutes after the last shock was administered.</description>
        <time_frame>At time of treatment (up to 1 day from admission)</time_frame>
        <population>Participants who had artrial fibrillation treated by either electrical or pharmacological cardioversion.</population>
        <group_list>
          <group group_id="O1">
            <title>Male</title>
            <description>Male participants with documented atrial fibrillation in the hospital setting for whom an electrical or pharmacological cardioversion was perfomed</description>
          </group>
          <group group_id="O2">
            <title>Female</title>
            <description>Female participants with documented atrial fibrillation in the hospital setting for whom an electrical or pharmacological cardioversion was perfomed</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion</title>
          <description>Pharmacological cardioversion was considered successful if sinus rhythm or atrial rhythm was obtained within 24 hours after its initiation. Electrical cardioversion was considered successful if sinus rhythm was obtained and maintained for at least 10 minutes after the last shock was administered.</description>
          <population>Participants who had artrial fibrillation treated by either electrical or pharmacological cardioversion.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2262"/>
                <count group_id="O2" value="1332"/>
                <count group_id="O3" value="3594"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Electrical Cardioversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5"/>
                    <measurement group_id="O2" value="55.1"/>
                    <measurement group_id="O3" value="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pharmacological Cardioversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5"/>
                    <measurement group_id="O2" value="44.9"/>
                    <measurement group_id="O3" value="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation</title>
        <time_frame>up to 60 days from day of treatment (cardioversion)</time_frame>
        <population>All enrolled participants with follow-up data available</population>
        <group_list>
          <group group_id="O1">
            <title>Male</title>
            <description>Male participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
          <group group_id="O2">
            <title>Female</title>
            <description>Female participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
          </group>
        </group_list>
        <measure>
          <title>Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation</title>
          <population>All enrolled participants with follow-up data available</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2633"/>
                <count group_id="O2" value="1507"/>
                <count group_id="O3" value="4140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-haemorrhagic Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemorrhagic Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient Ischaemic Attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence of Atrial Fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence of Atrial Flutter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asystole for more than 3 seconds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic Ventricular Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular Fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sick Sinus syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Torsade de pointes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Syncope</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocarditis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tamponade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No formal reporting or recording of adverse events was conducted during this observational study.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Enrolled Participants</title>
          <description>Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Scientific Committee for the study has the authority to make all decisions related to design, conduct, data interpretation and dissemination of study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

